ALK-Abelló A/S (0OIR.L)

141,09 +0,89 (+0,64%) Alla chiusura: 05:44PM BST

ALK-Abelló A/S

Bøge Allé 6-8
Horsholm 2970
Denmark
45 45 74 75 76
https://www.alk.net

Settore/i: 
Settore: 
Impiegati a tempo pieno: 2.824

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Claus Steensen Solje	Executive VP, CFO & Member of Management Board	14,12M	N/D	1972
Mr. Søren Daniel Niegel	Executive VP of Commercial Operations & Member of Management Board	5,33M	N/D	1971
Dr. Henriette Mersebach	Executive VP Research & Development & Member of Management Board	6,16M	N/D	1971
Ms. Katja Barnkob Thalund	Project Director of Global CMC Development & Employee-elected Director	350k	N/D	1969
Mr. Peter Halling	President & CEO	N/D	N/D	1977
Mr. Per Plotnikof	VP of Corporate Communications, Investor Relations & Strategic Planning and Head of IR	N/D	N/D	N/D
Prof. Hendrik Kees Kam Nolte M.D., Ph.D.	Senior Vice President of Research & Development - North America and International Markets	N/D	N/D	N/D
Mr. Christian G. Houghton	Head of Product Supply	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in DKK.

Descrizione

ALK-Abelló A/S operates as an allergy solutions company in Europe, North America, and internationally. Its product portfolio includes GRAZAX/GRASTEK, RAGWITEK/RAGWIZAX, ACARIZAX/ODACTRA, MITICURE, CEDARCURE, and ITULAZAX/ITULATEK for treatment of allergic rhinitis and allergic asthma. The company offers allergy immunotherapy products in the form of injections, sublingual drops, and tablets for the treatment of various allergies, including grass, ragweed, house dust mite, Japanese cedar, tree, and food. It also provides consumer healthcare solution, which include Digital eco-system, a platform which connect and engages with allergy sufferers in the disease journey through tools and e-commerce offerings that supports, guidance and relief, and smoothing the path to allergy immunotherapy treatment. In addition, the company offers diagnostic allergy solutions through testing by skin prick test or blood test; and emergency treatment, such as intra-muscular injection of adrenaline for the treatment of acute life-threatening allergic reactions, including Anaphylaxis. The company has a collaboration with Torii Pharmaceutical Co., Ltd. to develop, market and distribute allergy immunotherapy tablet for the treatment of grass pollen allergy. ALK-Abelló A/S was founded in 1923 and is headquartered in Horsholm, Denmark.

Governance aziendale

L'ISS Governance QualityScore di ALK-Abelló A/S al 1 aprile 2024 è 5. I criteri di valutazione fondamentali sono revisione: 1; Consiglio di Amministrazione: 2; diritti degli azionisti: 9; retribuzione: 7.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.